Leukemia Research
Volume 25, Issue 12 , Pages 1051-1057 , December 2001

CD44 isoforms are differentially regulated in plasma cell dyscrasias and CD44v9 represents a new independent prognostic parameter in multiple myeloma

  • W. Eisterer

      Affiliations

    • Department of Internal Medicine, Division of Haematology and Oncology, University Hospital, Anichstr. 35, 6020 Innsbruck, Austria
    • ,
  • O. Bechter

      Affiliations

    • Department of Internal Medicine, Division of Haematology and Oncology, University Hospital, Anichstr. 35, 6020 Innsbruck, Austria
    • ,
  • W. Hilbe

      Affiliations

    • Department of Internal Medicine, Division of Haematology and Oncology, University Hospital, Anichstr. 35, 6020 Innsbruck, Austria
    • ,
  • M. van Driel

      Affiliations

    • Department of Immunology, University Hospital, Utrecht, The Netherlands
    • ,
  • H.M. Lokhorst

      Affiliations

    • Department of Hematology, University Hospital, Utrecht, The Netherlands
    • ,
  • J. Thaler

      Affiliations

    • Department of Internal Medicine, Division of Haematology and Oncology, University Hospital, Anichstr. 35, 6020 Innsbruck, Austria
    • ,
  • A.C. Bloem

      Affiliations

    • Department of Immunology, University Hospital, Utrecht, The Netherlands
    • ,
  • U. Günthert

      Affiliations

    • Basel Institute for Immunology, Basel, Switzerland
    • ,
  • R. Stauder

      Affiliations

    • Department of Internal Medicine, Division of Haematology and Oncology, University Hospital, Anichstr. 35, 6020 Innsbruck, Austria
    • Corresponding Author InformationCorresponding author. Tel.: +43-512-5043341; fax: +43-512-5043341

Received 16 January 2001 ,Accepted 7 April 2001.

References 

  1. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol. 1993;54:271–335
  2. Stauder R, Günthert U. CD44 isoforms-impact on lymphocyte activation and differentiation. The Immunology. 1995;3:78–83
  3. Günthert U. A multitude of isoforms with diverse functions. Curr Top Microbiol Immunol. 1993;184:47–63
  4. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, et al.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991;65:13–24
  5. Seiter S, Arch R, Reber S, Komitowski D, Hofmann M, Ponta H, et al.  Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med. 1993;177:443–445
  6. Günthert U, Stauder R, Mayer B, Terpe HJ, Finke L, Friedrichs K. Are CD44 variant isoforms involved in human tumour progression?. Cancer Surv. 1995;24:19–42
  7. Koopman G, Heider KH, Horst E, Adolf GR, van den Berg F, Ponta H, et al.  Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med. 1993;177:897–904
  8. Stauder R, Eisterer W, Thaler J, Günthert U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood. 1995;85:2885–2899
  9. Salles G, Zain M, Jiang WM, Boussiotis VA, Shipp MA. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterisation and comparison with normal activated B cells and epithelial malignancies. Blood. 1993;82:3539–3547
  10. Terpe HJ, Koopman R, Imhof BA, Günthert U. Expression of integrins and CD44 isoforms in non-Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas. J Pathol. 1994;174:89–94
  11. Drillenburg P, Pals ST. Cell adhesion receptors in lymphoma dissemination. Blood. 2000;95:1900–1910
  12. Ghaffari S, Dougherty GJ, Eaves AC, Eaves CJ. Altered patterns of CD44 epitope expression in human chronic and acute myeloid leukemia. Leukemia. 1996;10:1773–1781
  13. Legras S, Günther U, Stauder R, Curt F, Oliferenko S, Kluin-Nelemans HC, et al.  A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia. Blood. 1998;91:3401–3413
  14. Stauder R, van Driel M, Schärzler C, Thaler J, Lokhorst HM, Kreuser ED, et al.  Different CD44 splicing patterns define prognostic subgroups in multiple myeloma. Blood. 1996;88:3101–3108
  15. van Driel M, Günthert U, Stauder R, Lokhorst H, Joling P, Bloem AC. CD44v variant isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma in different stages of disease. Leukemia. 1998;12:1821–1828
  16. Teoh G, Anderson KC. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am. 1997;11:27–42
  17. Degrassi A, Hilbert DM, Rudikoff S, Anderson AO, Potter M, Coon HG. In vitro culture of primary plasmacytomas requires stromal cell feeder layers. PNAS. 1993;90:2060–2064
  18. Lokhorst HM, Lamme T, de Smet M, Klein S, de Weger R, van Oers R, et al.  Primary tumor cells of myeloma patients induce IL-6 secretion in long term bone marrow cultures. Blood. 1994;84:2269–2277
  19. Okada T, Hawley RG. Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements. Int J Cancer. 1995;63:823–830
  20. Durie BGM. Staging and kinetics of multiple myeloma. Sem Oncol. 1986;13:300–309
  21. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–854
  22. Kyle RA, Lust JA. Monoclonal gammopathy of undetermined significance. Sem Haematol. 1989;26:176–200
  23. Eisterer W, Hilbe W, Fend F, Ludescher C, Falk M, Thaler J. Identification of a favorable subgroup of patients with generalized immunocytomas by follicular dendritic cells. Leukemia. 1995;9:254–259
  24. Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Günthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol. 1994;124:71–82
  25. Mackay CR, Maddox JF, Wijffels GL, Mackay R, Walker ID. Characterization of a 95000 molecule on sheep leucocytes homologous to murine Pgp-1 and human CD44. Immunology. 1988;65:93
  26. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457–481
  27. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187–220
  28. Asosingh K, Günthert U, Bakkus MH, De Raeve H, Goes E, Van Riet I, et al.  In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. Cancer Res. 2000;60:3096–3104
  29. van Driel M, Günthert U, van Kassel AC, Joling P, Stauder R, Lokhorst HM, et al. CD44 variant isoforms are involved in adhesion of myeloma plasma cells to bone marrow stromal cells, submitted for publication.
  30. Bartolazzi A, Jackson D, Bennett K, Aruffo A, Dickinson R, Shields J, et al.  Regulation of growth and dissemination of a human lymphoma by CD44 splice variants. J Cell Sci. 1995;108:1723–1733
  31. Cooper DL, Dougherty GJ. To metastasize or not? Selection of CD44 splice sites. Nature Med. 1995;1:635–637
  32. Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, Konig H, Weg-Remers S, et al.  CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann NY Acad Sci. 2000;910:106–120
  33. Bendall LJ, Bradstock KF, Gottlieb DJ. Expression of CD44 variant exons in acute myeloid leukemia is more common and more complex than that observed in normal blood, bone marrow or CD34+ cells. Leukemia. 2000;14:1239–1246
  34. Inagaki H, Banno S, Wakita A, Ueda R, Eimoto T. Prognostic significance of Cd44v6 in diffusse large B-cell lymphoma. Mod Pathol. 1999;12:546–552
  35. Kreuser ED, Günthert U, Streit M, Schwartz S, Stauder R, Komischke B, et al.  CD44 variant isoforms in adult acute lymphoblastic leukemia: evidence for different splicing patterns according to the phenotype. Blood. 1996;88(Suppl 1):77a
  36. Eisterer W, Hilbe W, Stauder R, Bechter O, Fend F, Thaler J. An aggressive subtype of B-CLL is characterized by strong CD44 expression and lack of CD11c. Brit J Haematol. 1996;93:661–669
  37. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med. 1994;330:484–489
  38. Hallek M, Bergsagel L, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3–21
  39. Merlini G, Waldenström JG, Jayakar SD. A new improved clinical staging system for multiple myeloma based on the analysis of 123 treated patients. Blood. 1980;55:1011–1019
  40. Medical Research Council's Working Party on Leukemia in Adults. Prognostic features in the third MRC myelomatosis trial. Br J Cancer 1980;42:831–40.
  41. Rajkumar SV, Greipp PR. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am. 1999;13:1295–1314
  42. Kyle R. Why better prognostic factors for multiple myeloma are needed. Blood. 1994;83:1713–1716
  43. Asosingh K, Günthert U, De Raeve H, Van Riet I, Van Camp B, Vanderkerken K. A unique pathway in the homing of murine multiple myeloma cells; CD44v10 mediates binding to bone marrow endothelium. Cancer Res. 2001;61:2862–2865
  44. Tzankov A, Günthert H, Kreuser ED, Stauder R. CD44v9 isoform expression correlates with relapse rate and overall survival in high risk acute lymphoblastic leukemia, in preparation.

PII: S0145-2126(01)00075-3

Leukemia Research
Volume 25, Issue 12 , Pages 1051-1057 , December 2001

Article Tools

* Image Usage & Resolution